Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.73 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylbutazone SCHEMBL8005041 | 0.93 | RAB9A (0.82) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL3632 | 0.93 | RAB9A (0.82) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL21694456 | 0.92 | RAB9A (0.80) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL7715162 | 0.92 | RAB9A (0.80) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL2874252 | 0.92 | RAB9A (0.80) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL10913190 | 0.92 | RAB9A (0.80) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL2122724 | 0.92 | RAB9A (0.80) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| SCHEMBL23295125 | 0.86 | LMNA (0.67) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Phenylbutazone SCHEMBL11269971 | 0.86 | ALDH1A1 (0.72) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 | |
| Oxyphenbutazone Anhydrous SCHEMBL25856 | 0.84 | LMNA (1.00) | ALDH1A1CYP3A4LMNAPTGS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-20220235134-A1 | ANTI-B7-H3 ANTIBODIES | SINGLE CELL TECHNOLOGY, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976660-A1 | ANTI-B7-H3 ANTIBODIES | Single Cell Technology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | ALDH1A1 4139/4885CYP3A4 4768/4885LMNA 4283/4885 |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | ALDH1A1 4098/4885CYP3A4 4843/4885LMNA 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.